Solved Jack, an exogenous drug at receptor X has a 100 fold
4.7 (250) · $ 22.50 · In stock
ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer
RAF inhibitors that evade paradoxical MAPK pathway activation
The glucocorticoid receptor represses, whereas C/EBPβ can enhance or repress CYP26A1 transcription - ScienceDirect
SOLVED: Jack, an exogenous drug at receptor X has a 100-fold LOWER AFFINITY than the endogenous ligand and is a SUPERAGONIST (150% of Emax). Jill, another exogenous drug at target X, has
Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy - ScienceDirect
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor
IJMS, Free Full-Text
Frontiers Alginate oligosaccharides increase boar semen quality by affecting gut microbiota and metabolites in blood and sperm
Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists
Frontiers Cytosolic DNA sensors and glial responses to endogenous DNA
Solved] 1. Jack, an exogenous drug at receptor X has a 100 fold lower
Lysosomal Delivery of a Lipophilic Gemcitabine Prodrug Using Novel Acid-Sensitive Micelles Improved Its Antitumor Activity
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection
